Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for ...

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...

A %Healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had ...